Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Bauer

Showing results (351-360 of 408) with videos related to

Pageof 41
Sort By:
Cancer Research Communications|June 11, 2026
Predicting clinical sensitivities of PDGFRA exon 18 mutations to imatinib and avapritinib to optimize gastrointestinal stromal tumor treatmentHomma M Khosroyani, Alina Teuber, Ajia Town, et al.
The EMBO Journal|May 11, 2017
A microRNA-129-5p/Rbfox crosstalk coordinates homeostatic downscaling of excitatory synapsesMarek Rajman, Franziska Metge, Roberto Fiore, et al.
The Lancet. Oncology|July 3, 2020
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trialMichael C Heinrich, Robin L Jones, Margaret von Mehren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2021
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III StudyYoon-Koo Kang, Suzanne George, Robin L Jones, et al.
JAMA|March 29, 2012
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trialHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Cancer Medicine|January 18, 2019
Desmoplastic small round cell tumors: Multimodality treatment and new risk factorsMonika Scheer, Christian Vokuhl, Bernd Blank, et al.
Journal of Cancer Research and Clinical Oncology|January 15, 2020
Synovial sarcoma disease characteristics and primary tumor sites differ between patient age groups: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS)Monika Scheer, Bernd Blank, Sebastian Bauer, et al.
Clinical Orthopaedics and Related Research|October 4, 2019
Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 TrialDimosthenis Andreou, Andreas Ranft, Georg Gosheger, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 19, 2012
The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy--an open-label, prospective, randomised controlled multicenter studyFelix Rosenow, Carmen Schade-Brittinger, Nicole Burchardi, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|January 9, 2026
How should primary pulmonary sarcoma be staged? Results of an International Multicenter AnalysisTheresa Stork, Dagmar Adamkova, Clemens Aigner, et al.
Pageof 41

Showing results (351-360 of 408) with videos related to

Sort By:
Pageof 41
Cancer Research Communications|June 11, 2026
Predicting clinical sensitivities of PDGFRA exon 18 mutations to imatinib and avapritinib to optimize gastrointestinal stromal tumor treatmentHomma M Khosroyani, Alina Teuber, Ajia Town, et al.
The EMBO Journal|May 11, 2017
A microRNA-129-5p/Rbfox crosstalk coordinates homeostatic downscaling of excitatory synapsesMarek Rajman, Franziska Metge, Roberto Fiore, et al.
The Lancet. Oncology|July 3, 2020
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trialMichael C Heinrich, Robin L Jones, Margaret von Mehren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2021
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III StudyYoon-Koo Kang, Suzanne George, Robin L Jones, et al.
JAMA|March 29, 2012
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trialHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Cancer Medicine|January 18, 2019
Desmoplastic small round cell tumors: Multimodality treatment and new risk factorsMonika Scheer, Christian Vokuhl, Bernd Blank, et al.
Journal of Cancer Research and Clinical Oncology|January 15, 2020
Synovial sarcoma disease characteristics and primary tumor sites differ between patient age groups: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS)Monika Scheer, Bernd Blank, Sebastian Bauer, et al.
Clinical Orthopaedics and Related Research|October 4, 2019
Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 TrialDimosthenis Andreou, Andreas Ranft, Georg Gosheger, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 19, 2012
The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy--an open-label, prospective, randomised controlled multicenter studyFelix Rosenow, Carmen Schade-Brittinger, Nicole Burchardi, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|January 9, 2026
How should primary pulmonary sarcoma be staged? Results of an International Multicenter AnalysisTheresa Stork, Dagmar Adamkova, Clemens Aigner, et al.
Pageof 41